Magnolol Causes Alterations in the Cell Cycle in Androgen Insensitive Human Prostate Cancer Cells In Vitro by Affecting Expression of Key Cell Cycle Regulatory Proteins

REFERENCES

• American Cancer Society: Global Cancer Facts and Figures (2nd ed.). American Cancer Society, Atlanta, 2011.
   Google Scholar
• Miyake H., Pollak M, and Gleave ME: Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60, 3058–3064, 2000.
   PubMed Web of Science ®Google Scholar
• Raghavan D., Koczwara B, and Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33, 566–574, 1997.
   PubMed Web of Science ®Google Scholar
• Bemis DL, Capodice JL, Costello JE, Vorys GC, Katz AE, et al.: The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer. Curr Urol Rep 7, 166–174, 2006.
   PubMedGoogle Scholar
• Ikarashi Y, Yuzurihara M, Sakakibara I, Nakai Y, Hattori N, et al.: Effects of the extract of the bark of magnolia obovata and its biphenolic constituents magnolol and honokiol on histamine release from peritoneal mast cells in rats. Planta Med 67, 709–713, 2001.
   PubMed Web of Science ®Google Scholar
• Zhang WW, Li Y, Wang XQ, Tian F, Cao H, et al.: Effects of magnolol and honokiol derived from traditional chinese herbal remedies on gastrointestinal movement. World J Gastroenterol 11, 4414–4418, 2005.
   PubMed Web of Science ®Google Scholar
• Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu K, et al.: Magnolol down-regulates her2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett 311, 11–19, 2011.
   PubMed Web of Science ®Google Scholar
• Hsu YF, Lee TS, Lin SY, Hsu SP, Juan SH, et al.: Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells. Mol Carcinog 46, 275–283, 2007.
   PubMed Web of Science ®Google Scholar
• Hwang ES and Park KK: Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci, Biotechnol Biochem 74, 961–967, 2010.
   PubMed Web of Science ®Google Scholar
• Kim HM, Bae SJ, Kim DW, Kim BK, Lee SB, et al.: Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-α-induced vascular smooth muscle cells. Int Immunopharm 7, 1083–1091, 2007.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho YH, Park K, Kim EJ, Jung KH, et al.: Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells. Biochem Pharmacol 75, 2289–2300, 2008.
   PubMed Web of Science ®Google Scholar
• Lee DH, Szczepanski MJ, and Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 106, 1113–1122, 2009.
   PubMed Web of Science ®Google Scholar
• Lin SY, Chang YT, Liu JD, Yu CH, Ho YS, et al.: Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Molecular Carcinogenesis 32, 73–83, 2001.
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, et al.: Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 84, 532–544, 2002.
   PubMed Web of Science ®Google Scholar
• Rasul A, Yu B, Khan M, Zhang K, Igbal F, et al.: Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. Int J Oncol 40, 1153–1161, 2012.
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chou CJ, and Chen CF: Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 48, 57–59, 1996.
   PubMed Web of Science ®Google Scholar
• Lin SP, Tsai SY, Chao PDL, Chen YC, and Hou YC: Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med 77, 1800–1805, 2011.
   PubMed Web of Science ®Google Scholar
• Ho JHC and Hong CY: Cardiovascular protection of magnolol: cell-type specific and dose-related effects. J Biomed Sci 19, 70, 2012.
   PubMed Web of Science ®Google Scholar
• Homma M, Oka K, Kobayashi H, Nitsuma T, Yamaoto S, et al.: Impact of free magnolol excretions in asthmatic patients who responded well to saiboku-to, a Chinese herbal medicine. J Pharm Pharmacol 45, 844–846, 1993.
   PubMed Web of Science ®Google Scholar
• Li N, Song Y, Zhang W, Wang W, Chen J, et al.: Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul Toxicol Pharmacol 49, 154–159, 2007.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang X, Cui W, Zhang X, Li N, et al.: Evaluation of Short-Term and Subchronic Toxicity of Magnolia Bark Extract in Rats. Regul Toxicol Pharmacol 49, 160–171, 2007.
   PubMed Web of Science ®Google Scholar
• Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144, 646–674, 2011.
   PubMed Web of Science ®Google Scholar
• Chen LC, Liu YC, Liang YC, Ho YS, and Lee WS: Magnolol inhibits glioblastoma cell proliferation though upregulation of p21/Cip1. J Agric Food Chem 57, 7331–7337, 2009.
   PubMed Web of Science ®Google Scholar
• Hahm ER. and Singh SV: Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 6, 2686–2695, 2007.
   PubMed Web of Science ®Google Scholar
• Wolf I, O’Kelly J, Wakimoto N, Nguyen A, Amblard F, et al.: Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Intern J Oncol 30, 1529–1537, 2007.
   PubMed Web of Science ®Google Scholar
• Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23, 9408–9421, 2005.
   PubMed Web of Science ®Google Scholar
• Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39, 295–312, 1999.
   PubMed Web of Science ®Google Scholar
• Verneulen K, Van Bockstaele DR, and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131–149, 2003.
   PubMed Web of Science ®Google Scholar
• Eto I.: Expression of p27Kip1, a cell cycle repressor protein, is inversely associated with potential carcinogenic risk in the genetic rodent models of obesity and long-lived Ames Dwarf mice. Metabolism 62, 873–887, 2013.
   PubMed Web of Science ®Google Scholar
• Leng X, Noble M, Adams PD, Qin J, and Harper JW: Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol Cell Biol 22, 2242–2254, 2002.
   PubMed Web of Science ®Google Scholar
• Bruce JL, Hurford RK, Jr., Classon M, Koh J, and Dyson N: Requirements for cell cycle arrest by p16INK4a. Mol Cell 6, 737–742, 2000.
   PubMed Web of Science ®Google Scholar
• Mayol X and Graña X: pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. Prog Cell Cycle Res 3, 157–169, 1997.
   PubMedGoogle Scholar
• Smith EJ, Leone G, DeGregori J, Jakoi L, and Nevins JR: The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol Cell Biol 16, 6965–6976, 1996.
   PubMed Web of Science ®Google Scholar